The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance: A Meta-analysis
Open accessAbstract
Context: Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain. Objective: To assess the efficacy and safety of ephedra and ephedrine used for weight loss and enhanced athletic performance. Data Sources: We searched 9 databases using the terms ephedra , ephedrine , adverse effect , side effect , efficacy , effective , and toxic . We included unpublished trials and non–English-language documents. Adverse events reported to the US Food and Drug Administration MedWatch program were assessed. Study Selection: Eligible studies were controlled trials of ephedra or ephedrine used for weight loss or athletic performance and case reports of adverse events associated with such use. Eligible studies for weight loss were human studies with at least 8 weeks of follow-up; and for athletic performance, those having no minimum follow-up. Eligible case reports documented that ephedra or ephedrine was consumed within 24 hours prior to an adverse event or that ephedrine or an associated product was found in blood or urine, and that other potential causes had been excluded. Of the 530 articles screened, 52 controlled trials and 65 case reports were included in the adverse events analysis. Of more than 18 000 other case reports screened, 284 underwent detailed review. Data Extraction: Two reviewers independently identified trials of efficacy and safety of ephedra and ephedrine on weight loss or athletic performance; disagreements were resolved by consensus. Case reports were reviewed with explicit and implicit methods. Data Synthesis: No weight loss trials assessed duration of treatment greater than 6 months. Pooled results for trials comparing placebo with ephedrine (n = 5), ephedrine and caffeine (n = 12), ephedra (n = 1), and ephedra and herbs containing caffeine (n = 4) yielded estimates of weight loss (more than placebo) of 0.6 (95% confidence interval, 0.2-1.0), 1.0 (0.7-1.3), 0.8 (0.4-1.2), and 1.0 (0.6-1.3) kg/mo, respectively. Sensitivity analyses did not substantially alter the latter 3 results. No trials of ephedra and athletic performance were found; 7 trials of ephedrine were too heterogeneous to synthesize. Safety data from 50 trials yielded estimates of 2.2- to 3.6-fold increases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations. Data are insufficient to draw conclusions about adverse events occurring at a rate less than 1.0 per thousand. The majority of case reports are insufficiently documented to allow meaningful assessment. Conclusions: Ephedrine and ephedra promote modest short-term weight loss (≈0.9 kg/mo more than placebo) in clinical trials. There are no data regarding long-term weight loss, and evidence to support use of ephedra for athletic performance is insufficient. Use of ephedra or ephedrine and caffeine is associated with increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, ephedrine is associated with increased risk of psychiatric, autonomic, gastrointestinal, and cardiovascular symptoms 134, which likely will preclude the use of ephedrine itself for the treatment of obesity.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [134]
In the citing paper
“A meta-analysis of several dozen trials showed that ephedrine promotes modest short-term weight loss, but there are no data on longer-term efficacy 134.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [134]
In the citing paper
“Unfortunately, ephedrine is associated with increased risk of psychiatric, autonomic, gastrointestinal, and cardiovascular symptoms 134, which likely will preclude the use of ephedrine itself for the treatment of obesity.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
A random‐effects regression model for meta‐analysis
Berkey, C. S., Hoaglin, D. C., Mosteller, F. C., & Colditz, G. A. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140406 · Cited by 896
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287 · cited 8×
“Molnar et al,27 2000 4 Ephedrine (30-60) and caffeine (100 for 1 wk) 20 wk 16 16 0.”
InfluentialLong-term Weight Loss With Sibutramine
Wirth, A. G., & Krause, J. (2001) · JAMA · doi:10.1001/jama.286.11.1331 · Cited by 267
Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244
An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial
Boozer, C., Nasser, J., Heymsfield, S. B., Wang, V., Chen, G., & Solomon, J. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801539 · Cited by 240
Comparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215
Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial
Boozer, C., Daly, P., Homel, P., Solomon, J., Blanchard, D., Nasser, J., Strauss, R., & Meredith, T. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802023 · Cited by 203
Toubro, S., & Astrup, A. (1997) · BMJ · doi:10.1136/bmj.314.7073.29 · Cited by 198
Effect of caffeine and ephedrine ingestion on anaerobic exercise performance
Bell, D. G., Jacobs, I. A., & ELLERINGTON, K. (2001) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200108000-00024 · Cited by 186
L Van Gaal for the ObelHyx Study Group, Muls, E., Kolanowski, J., Scheen, A. J., & Gaal, L. V. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801814 · Cited by 166
The Relative Safety of Ephedra Compared with Other Herbal Products
Bent, S., Tiedt, T. N., Odden, M. C., & Shlipak, M. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-6-200303180-00010 · Cited by 165
Smith, I. G., & Goulder, M. A. (2001) · PubMed · Cited by 151
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
van Gaal, L. V., Broom, J., Enzi, G., & Toplak, H. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050433 · Cited by 142
Morton, R. H. (1999) · European Journal of Applied Physiology · doi:10.1007/s004210050524 · Cited by 103
Effects of Sibutramine in Obese Female Subjects With Type 2 Diabetes and Poor Blood Glucose Control
Gökçel, A., Karakose, H., Ertörer, M. E., Tanaci, N., Tütüncü, N. B., & Guvener, N. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1957 · Cited by 100
Molnár, D., Török, K., Erhardt, É., & Jeges, S. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801433 · Cited by 97
Bell, D. G., Jacobs, I., & Zamecnik, J. (1998) · European Journal of Applied Physiology · doi:10.1007/s004210050355 · Cited by 96
Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity.
Daly, P. A., Krieger, D., Dulloo, A. G., Young, J. B., & Landsberg, L. (1993) · PubMed · Cited by 84
Use of Ephedra -containing products and risk for hemorrhagic stroke
Morgenstern, L. B., Viscoli, C. M., Kernan, W. N., Brass, L. M., Broderick, J. P., Feldmann, E. G., Wilterdink, J. L., Brott, T. G., & Horwitz, R. I. (2003) · Neurology · doi:10.1212/01.wnl.0000042092.20411.5b · Cited by 81
The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
Astrup, A. V., Buemann, B., Christensen, N. J., Toubro, S., Thorbek, G., Victor, O. J., & QUAADE, F. (1992) · Metabolism · doi:10.1016/0026-0495(92)90304-s · Cited by 80
Karhunen, L. J., Franssila-Kallunki, A., Rissanen, P., Valve, R., Kolehmainen, M., Rissanen, A., & Uusitupa, M. I. J. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801443 · Cited by 71
Ephedrine as an anorectic: the story of the 'Elsinore pill'.
Malchow-møller, A., Larsen, S., Hey, H., Kh, S., Juhl, E., & QUAADE, F. (1981) · PubMed · Cited by 60
Activity related energy expenditure in children and adolescents with Prader–Willi syndrome
van Mil, E., Westerterp, K. R., Kester, A. D. M., Curfs, L., Gerver, W. J. M., Schrander-Stumpel, C. T. R. M., & Saris, W. H. M. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801175 · Cited by 54
A controlled trial using ephedrine in the treatment of obesity.
Pasquali, R., Baraldi, G., Cesari, M. P., Melchionda, N., Zamboni, M. M., Stefanini, C., & Raitano, A. (1985) · PubMed · Cited by 48
Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test.
Bell, D. G., & Jacobs, I. A. (1999) · PubMed · Cited by 47
Evaluation of Drugs for Treating Obesity
Bray, G. A. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00209.x · Cited by 47
Kalman, D., Colker, C. M., Shi, Q., & Swain, M. A. (2000) · Current Therapeutic Research · doi:10.1016/s0011-393x(00)89034-7 · Cited by 45
Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect.
Bell, D. G., Jacobs, I. A., McLellan, T. M., & Zamecnik, J. (2000) · PubMed · Cited by 44
Sidney, K. H., & Lefcoe, N. M. (1977) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-197709020-00004 · Cited by 38
Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion.
Bell, D. G., Jacobs, I. A., Tm, M., Miyazaki, M., & Sabiston, C. M. (1999) · PubMed · Cited by 31
The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet.
Buemann, B., Marckmann, P., Christensen, N. J., & Astrup, A. V. (1994) · PubMed · Cited by 21
Micić, D., Ivkovic-Lazar, T., Dragojević, R., Jorga, J. B., Stokić, E., & Hajdukovic, Z. (1999) · PubMed · Cited by 14
The Relative Safety of Ephedra Compared with Other Herbal Products
Dickinson, A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00019 · Cited by 4
[Aerobic training increases the effect of ephedrine on energy expenditure].
Oksbjerg, N., Meyer, T., & Hvid-Jacobsen, K. (1986) · PubMed · Cited by 2
Effects of Ingesting Caffeine and Ephedrine on Muscular Endurance.
&NA; (2000) · Clinical Journal of Sport Medicine · doi:10.1097/00042752-200007000-00046 · Cited by 1
Research works printed but not linked: 13
- Abrahamson, 2001, Wheeler used supplement., Los Angeles Times
- Carey, 2001, Risks of ephedra usage in spotlight., Los Angeles Times
- Marsa, 2002, A tug of war in a larger battle: ephedra is now under intense scrutiny., Los Angeles Times
- Moheb, 1998, Effect of ephedrine, caffeine, and aspirin, in combinations of weight loss in obese women [abstract]., Int J Obes Relat Metab Disord, 22, S264
- Colker, 2001, A pilot study evaluating the effects of an ephedrine and forskolin-based product on body weight and body composition in overweight, healthy women [abstract]., J Am Coll Nutr, 20, 98
- Jensen, 1980, Elsinore tablets and ephedrine as slimming agents [in Danish]., Ugeskr Laeger, 142, 1499
- Kettle, 1998, Ephedrine/caffeine enhances abdominal fat loss in females., Int J Obes Relat Metab Disord, 22, S264
- Lumholtz, 1980, Ephedrine in the treatment of obesity [in Danish]., Ugeskr Laeger, 142, 1487
- Quaade, 1992, The effect of an ephedrine/caffeine combination as a supplement to a weight-reducing diet [in Danish]., Ugeskr Laeger, 154, 1258
- Roed, 1980, Elsinore banting tablets [in Danish]., Ugeskr Laeger, 142, 1491
- Breum, 1994, Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity., Int J Obes Relat Metab Disord, 18, 99
- Not Available, 2001, >Stata [computer program].
- Not Available, 2000, StatXact 4 [computer program].
Cited by
Sorted by citations
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Bent, S. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0632-y · Cited by 611
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
Dietary supplements for body-weight reduction: a systematic review
Pittler, M. H., & Ernst, E. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.529 · Cited by 378
Brown fat as a therapy for obesity and diabetes
Cypess, A. M., & Kahn, C. R. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328337a81f · Cited by 376
Metadata
- Authors
- Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J.
- Affiliations
- RAND Corporation (US)
- Cedars-Sinai Medical Center (US)
- University of Southern California (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-03-26
- Volume
- 289
- Issue
- 12
- Pages
- 1537
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1999289755
- Cited by
- 511
- References
- 43
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 15 · 2021: 15 · 2020: 9 · 2019: 15 · 2018: 16 · 2017: 16 · 2016: 19 · 2015: 21 · 2014: 20 · 2013: 17 · 2012: 23
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- VTechWorks (Virginia Tech) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Health Services Research and Development
- U.S. Public Health Service (290-97-0001)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Sociology and Political Science › Doping in Sports
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
- Keywords
- Ephedra, ephedrine, weight loss, athletic performance, stimulants, caffeine, adverse events, drug safety, efficacy, herbal supplements, performance-enhancing drugs
- MeSH terms
- Caffeine, Ephedrine, Humans, Physical Endurance, Risk, Sports, Weight Loss, Randomized Controlled Trials as Topic, Controlled Clinical Trials as Topic, Anti-Obesity Agents, Dietary Supplements, Plant Preparations, Ephedra
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
